Zafirlukast is a leukotriene receptor antagonist used for prophylaxis and chronic treatment of asthma. It is available as a tablet and is usually dosed twice daily.
- Mechanism
- Curator reviewed
Zafirlukast is a selective and competitive receptor antagonist of leukotriene D4 and E4 (LTD4 and LTE4), components of slow-reacting substance of anaphylaxis (SRSA). Cysteinyl leukotriene production and receptor occupation have been correlated with the pathophysiology of asthma, including airway edema, smooth muscle constriction, and altered cellular activity associated with the inflammatory process, which contribute to the signs and symptoms of asthma.
- Primary indication
- For the prophylaxis and chronic treatment of asthma.Curator reviewed · 2 structured indications
- Formula / weight
- C31H33N3O6S · 575.675 g/mol (avg)
- First approval
- Canada, 2000 · United States, 1996
- Code names
- ICI-204,219
- Brand names
Resolves to
YEEZWCHGZNKEEK-UHFFFAOYSA-NSMILESCOC1=CC(=CC=C1CC1=CN(C)C2=C1C=C(NC(=O)OC1CCCC1)C=C2)C(=O)NS(=O)(=O)C1=CC=CC=C1CWhat you can answer from here — as of September 28, 2026
Which drugs share a target with Zafirlukast, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account